Lynx Investment Advisory’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$630K Buy
4,906
+1,585
+48% +$186K 0.21% 120
2026
Q1
$400K Sell
3,321
-468
-12% -$54K 0.19% 117
2025
Q4
$399K Sell
3,789
-183
-5% -$17.2K 0.22% 107
2025
Q3
$333K Hold
3,972
0.2% 110
2025
Q2
$314K Buy
3,972
+563
+17% +$44.8K 0.21% 108
2025
Q1
$306K Buy
3,409
+344
+11% +$32.1K 0.2% 111
2024
Q4
$305K Buy
3,065
+136
+5% +$14K 0.21% 108
2024
Q3
$333K Buy
2,929
+669
+30% +$79.5K 0.24% 93
2024
Q2
$280K Buy
+2,260
New +$291K 0.21% 101

Other funds holding MRK

Lynx Investment Advisory's MRK Position: Q2 2026 in Review

Lynx Investment Advisory increased its Merck (MRK) stake by 48% in Q2 2026, buying an estimated $186K and bringing the position to 4,906 shares worth $630K. The position accounts for 0.21% of the portfolio, ranked #120.

Lynx Investment Advisory first reported a position in MRK in Q2 2024 and has held it in 9 quarters since. 1,769 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Lynx Investment Advisory held 4,906 shares of Merck worth $630K as of Q2 2026.
  • Lynx Investment Advisory bought 1,585 Merck shares in Q2 2026, an estimated $186K.
  • Merck made up 0.21% of Lynx Investment Advisory's portfolio in Q2 2026, its #120 holding.
  • Lynx Investment Advisory first reported a position in Merck in Q2 2024 and has held it in 9 quarters since.
  • 1,769 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Lynx Investment Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.